IL6 and neoplasm: Directly, IL-6 binds to its receptor on tumor cells and activates the STAT3 signaling pathway, which will lead to tumor progression through cyclin D1 and the proto-oncogene c-myc, an important regulator of the progression of G1 to S phase of the cell cycle (37).